Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663754 | 0.76 | PDE4D (0.59) | PDE4DDYRK1ALMNAL3MBTL1CYP2C19 | |
| SCHEMBL1640767 | 0.76 | PDE4D (0.59) | PDE4DDYRK1ALMNAL3MBTL1CYP2C19 | |
| SCHEMBL15777023 | 0.74 | PDE4D (0.57) | PDE4DDYRK1ALMNAL3MBTL1CYP2C19 | |
| SCHEMBL23926008 | 0.74 | PDE4D (0.57) | PDE4DDYRK1ALMNAL3MBTL1CYP2C19 | |
| SCHEMBL4754626 | 0.72 | PDE4D (0.66) | PDE4DDYRK1ALMNAL3MBTL1CYP2C19 | |
| SCHEMBL352117 | 0.71 | PDE4D (0.53) | PDE4DDYRK1ALMNAL3MBTL1CYP2C19 | |
| SCHEMBL10858885 | 0.71 | PDE4D (0.63) | PDE4DDYRK1ALMNAL3MBTL1CYP2C19 | |
| SCHEMBL10839267 | 0.69 | PDE4D (0.56) | PDE4DDYRK1ALMNAL3MBTL1CYP2C19 | |
| SCHEMBL353564 | 0.69 | PDE4D (1.00) | PDE4DLMNAL3MBTL1CYP2C19GAA | |
| SCHEMBL11840466 | 0.69 | PDE4D (0.52) | PDE4DDYRK1ALMNAL3MBTL1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962551-B2 | Quinoxalinyl derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8268777-B2 | Oximyl macrocyclic derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8193346-B2 | Process for making macrocyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| WO-2009073713-A1 | OXIMYL MACROCYCLIC DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009073719-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | SQOR, ATG4A, NQO1 | PDE4D 1147/4885DYRK1A 4397/4885LMNA 2171/4885 |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | CYP3A4, CYP4A22, HCCS | PDE4D 1663/4885DYRK1A 4744/4885LMNA 3042/4885 |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | PREP, HCCS, PEPD | PDE4D 4440/4885DYRK1A 4250/4885LMNA 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.